HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC)

Journal of Pharmaceutical and Biomedical Analysis

Volumn 59, Issue 1, 2012, Pages 109-116

  D'Avolio, Antonio ^a   Simiele, Marco ^a   De Francia, Silvia ^b   Ariaudo, Alessandra ^b   Baietto, Lorena ^a   Cusato, Jessica ^a   Fava, Carmen ^b   Saglio, Giuseppe ^b   Di Carlo, Francesco ^b   Di Perri, Giovanni ^a  

^a AMEDEO DI SAVOIA HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Dasatinib; HPLC MS; Imatinib; Intracellular quantification; Nilotinib

Indexed keywords

ACETONITRILE; DASATINIB; FORMIC ACID; IMATINIB; NILOTINIB; QUINOXALINE;

ARTICLE; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CALIBRATION; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKOCYTES, MONONUCLEAR; LIMIT OF DETECTION; MASS SPECTROMETRY; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; THIAZOLES;

EID: 82255179202     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.10.003     Document Type: Article

References (60)

1. Sawyers C.L. Chronic myeloid leukemia. N. Engl. J. Med. 1999, 340:1330-1340.
2. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., Lydon N.B., Kantarjian H., Capdeville R., Ohno-Jones S., Sawyers C.L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 2001, 344:1031-1037.
3. Bakhtiar R., Khemani L., Hayes M., Bedman T., Tse F. Quantification of the anti-leukemia drug STI571 (Gleevec) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry. J. Pharm. Biomed. Anal. 2002, 28:1183-1194.
4. Druker B.J. Imatinib as a paradigm of targeted therapies. Adv. Cancer. Res. 2004, 91:1-30.
5. Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., Deininger M.W., Silver R.T., Goldman J.M., Stone R.M., Cervantes F., Hochhaus A., Powell B.L., Gabrilove J.L., Rousselot P., Reiffers J., Cornelissen J.J., Hughes T., Agis H., Fischer T., Verhoef G., Shepherd J., Saglio G., Gratwohl A., Nielsen J.L., Radich J.P., Simonsson B., Taylor K., Baccarani M., So C., Letvak L., Larson R.A. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 2006, 355:2408-2417.
6. Hughes T.P., Kaeda J., Branford S., Rudzki Z., Hochhaus A., Hensley M.L., Gathmann I., Bolton A.E., van Hoomissen I.C., Goldman J.M., Radich J.P. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 2003, 349:1423-1432.
7. O'Brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F., Cornelissen J.J., Fischer T., Hochhaus A., Hughes T., Lechner K., Nielsen J.L., Rousselot P., Reiffers J., Saglio G., Shepherd J., Simonsson B., Gratwohl A., Goldman J.M., Kantarjian H., Taylor K., Verhoef G., Bolton A.E., Capdeville R., Druker B.J. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 2003, 348:994-1004.
8. Hughes T.P., Hochhaus A., Branford S., Muller M.C., Kaeda J.S., Foroni L., Druker B.J., Guilhot F., Larson R.A., O'Brien S.G., Rudoltz M.S., Mone M., Wehrle E., Modur V., Goldman J.M., Radich J.P. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 2010, 116:3758-3765.
9. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., Sawyers C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876-880.
10. Shah N.P., Sawyers C.L. Mechanisms of resistance to STI571 in philadelphia chromosome-associated leukemias. Oncogene 2003, 22:7389-7395.
11. Kamath A.V., Wang J., Lee F.Y., Marathe P.H. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemother. Pharmacol. 2008, 61:365-376.
12. Lombardo L.J., Lee F.Y., Chen P., Norris D., Barrish J.C., Behnia K., Castaneda S., Cornelius L.A., Das J., Doweyko A.M., Fairchild C., Hunt J.T., Inigo I., Johnston K., Kamath A., Kan D., Klei H., Marathe P., Pang S., Peterson R., Pitt S., Schieven G.L., Schmidt R.J., Tokarski J., Wen M.L., Wityak J., Borzilleri R.M. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 2004, 47:6658-6661.
13. Frame M.C. Src in cancer: deregulation and consequences for cell behaviour. Biochim. Biophys. Acta 2002, 1602:114-130.
14. Steinberg M. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Clin. Ther. 2007, 29:2289-2308.
15. Kantarjian H., Giles F., Wunderle L., Bhalla K., O'Brien S., Wassmann B., Tanaka C., Manley P., Rae P., Mietlowski W., Bochinski K., Hochhaus A., Griffin J.D., Hoelzer D., Albitar M., Dugan M., Cortes J., Alland L., Ottmann O.G. Nilotinib in imatinib-resistant CML and philadelphia chromosome-positive ALL. N. Engl. J. Med. 2006, 354:2542-2551.
16. Weisberg E., Manley P.W., Breitenstein W., Bruggen J., Cowan-Jacob S.W., Ray A., Huntly B., Fabbro D., Fendrich G., Hall-Meyers E., Kung A.L., Mestan J., Daley G.Q., Callahan L., Catley L., Cavazza C., Azam M., Neuberg D., Wright R.D., Gilliland D.G., Griffin J.D. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005, 7:129-141.
17. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., Carbone P.P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 1982, 5:649-655.
18. Sokal J.E., Cox E.B., Baccarani M., Tura S., Gomez G.A., Robertson J.E., Tso C.Y., Braun T.J., Clarkson B.D., Cervantes F., et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984, 63:789-799.
19. Saglio G., Kim D.W., Issaragrisil S., le Coutre P., Etienne G., Lobo C., Pasquini R., Clark R.E., Hochhaus A., Hughes T.P., Gallagher N., Hoenekopp A., Dong M., Haque A., Larson R.A., Kantarjian H.M. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 2010, 362:2251-2259.
20. Baccarani M., Saglio G., Goldman J., Hochhaus A., Simonsson B., Appelbaum F., Apperley J., Cervantes F., Cortes J., Deininger M., Gratwohl A., Guilhot F., Horowitz M., Hughes T., Kantarjian H., Larson R., Niederwieser D., Silver R., Hehlmann R. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood 2006, 108:1809-1820.
21. Singh N., Kumar L., Meena R., Velpandian T. Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders. Eur. J. Clin. Pharmacol. 2009, 65:545-549.
22. Awidi A., Salem, Najib N., Mefleh R., Tarawneh B. Determination of imatinib plasma levels in patients with chronic myeloid leukemia by high performance liquid chromatography-ultraviolet detection and liquid chromatography-tandem mass spectrometry: methods' comparison. Leuk. Res. 2010, 34:714-717.
23. Bouchet S., Chauzit E., Ducint D., Castaing N., Canal-Raffin M., Moore N., Titier K., Molimard M. Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS. Clin. Chim. Acta 2011, 412:1060-1067.
24. Davies A., Hayes A.K., Knight K., Watmough S.J., Pirmohamed M., Clark R.E. Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography. Leuk. Res. 2010, 34:702-707.
25. De Francia S., D'Avolio A., De Martino F., Pirro E., Baietto L., Siccardi M., Simiele M., Racca S., Saglio G., Di Carlo F., Di Perri G. New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2009, 877:1721-1726.
26. Klawitter J., Zhang Y.L., Anderson N., Serkova N.J., Christians U. Development and validation of a sensitive assay for the quantification of imatinib using LC/LC-MS/MS in human whole blood and cell culture. Biomed. Chromatogr. 2009, 23:1251-1258.
27. Micova K., Friedecky D., Faber E., Polynkova A., Adam T. Flow injection analysis vs. ultra high performance liquid chromatography coupled with tandem mass spectrometry for determination of imatinib in human plasma. Clin. Chim. Acta 2010, 411:1957-1962.
28. Miura M., Takahashi N., Sawada K. High-performance liquid chromatography with solid-phase extraction for the quantitative determination of nilotinib in human plasma. Biomed. Chromatogr. 2010, 24:789-793.
29. Miura M., Takahashi N., Sawada K. Quantitative determination of imatinib in human plasma with high-performance liquid chromatography and ultraviolet detection. J. Chromatogr. Sci. 2011, 49:412-415.
30. Oostendorp R.L., Beijnen J.H., Schellens J.H., Tellingen O. Determination of imatinib mesylate and its main metabolite (CGP74588) in human plasma and murine specimens by ion-pairing reversed-phase high-performance liquid chromatography. Biomed. Chromatogr. 2007, 21:747-754.
31. Parise R.A., Egorin M.J., Christner S.M., Shah D.D., Zhou W., Beumer J.H. A high-performance liquid chromatography-mass spectrometry assay for quantitation of the tyrosine kinase inhibitor nilotinib in human plasma and serum. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2009, 877:1894-1900.
32. Pursche S., Ottmann O.G., Ehninger G., Schleyer E. High-performance liquid chromatography method with ultraviolet detection for the quantification of the BCR-ABL inhibitor nilotinib (AMN107) in plasma, urine, culture medium and cell preparations. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2007, 852:208-216.
33. Roth O., Spreux-Varoquaux O., Bouchet S., Rousselot P., Castaigne S., Rigaudeau S., Raggueneau V., Therond P., Devillier P., Molimard M., Maneglier B. Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: comparison with LC-MS/MS. Clin. Chim. Acta 2010, 411:140-146.
34. Titier K., Picard S., Ducint D., Teilhet E., Moore N., Berthaud P., Mahon F.X., Molimard M. Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. Ther. Drug Monit. 2005, 27:634-640.
35. Yuki M., Yamakawa Y., Uchida T., Nambu T., Kawaguchi T., Hamada A., Saito H. High-performance liquid chromatographic assay for the determination of nilotinib in human plasma. Biol. Pharm. Bull. 2011, 34:1126-1128.
36. Awidi A., Ayed A.O., Bsoul N., Magablah A., Mefleh R., Dweiri M., Ramahi M., Arafat E., Bishtawi M., Marie L. Relationship of serum imatinib trough level and response in CML patients: long term follow-up. Leuk. Res. 2010, 34:1573-1575.
37. Faber E., Friedecky D., Micova K., Divoka M., Katrincsakova B., Rozmanova S., Jarosova M., Indrak K., Adam T. Imatinib dose escalation in two patients with chronic myeloid leukemia, with low trough imatinib plasma levels measured at various intervals from the beginning of therapy and with suboptimal treatment response, leads to the achievement of higher plasma levels and major molecular response. Int. J. Hematol. 2010, 91:897-902.
38. Peng B., Hayes M., Resta D., Racine-Poon A., Druker B.J., Talpaz M., Sawyers C.L., Rosamilia M., Ford J., Lloyd P., Capdeville R. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J. Clin. Oncol. 2004, 22:935-942.
39. Picard S., Titier K., Etienne G., Teilhet E., Ducint D., Bernard M.A., Lassalle R., Marit G., Reiffers J., Begaud B., Moore N., Molimard M., Mahon F.X. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007, 109:3496-3499.
40. Holdhoff M., Supko J.G., Gallia G.L., Hann C.L., Bonekamp D., Ye X., Cao B., Olivi A., Grossman S.A. Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme. J. Neurooncol. 2010, 97:241-245.
41. Roche S., McMahon G., Clynes M., O'Connor R. Development of a high-performance liquid chromatographic-mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2009, 877:3982-3990.
42. Nambu T., Hamada A., Nakashima R., Yuki M., Kawaguchi T., Mitsuya H., Saito H. Association of SLCO1B3 polymorphism with intracellular accumulation of imatinib in leukocytes in patients with chronic myeloid leukemia. Biol. Pharm. Bull. 2011, 34:114-119.
43. Colombo S., Beguin A., Telenti A., Biollaz J., Buclin T., Rochat B., Decosterd L.A. Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2005, 819:259-276.
44. D'Avolio A., Simiele M., Siccardi M., Baietto L., Sciandra M., Oddone V., Stefani F.R., Agati S., Cusato J., Bonora S., Di Perri G. A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. J. Pharm. Biomed. Anal. 2011, 54:779-788.
45. Ford J., Khoo S.H., Back D.J. The intracellular pharmacology of antiretroviral protease inhibitors. J. Antimicrob. Chemother. 2004, 54:982-990.
46. Khoo S.H., Hoggard P.G., Williams I., Meaden E.R., Newton P., Wilkins E.G., Smith A., Tjia J.F., Lloyd J., Jones K., Beeching N., Carey P., Peters B., Back D.J. Intracellular accumulation of human immunodeficiency virus protease inhibitors. Antimicrob. Agents Chemother. 2002, 46:3228-3235.
47. Simiele M., D'Avolio A., Baietto L., Siccardi M., Sciandra M., Agati S., Cusato J., Bonora S., Di Perri G. Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations. Antimicrob. Agents Chemother. 2011, 55:2976-2978.
48. Taylor P.J. Matrix effects: the Achilles heel of quantitative high-performance liquid chromatography-electrospray-tandem mass spectrometry. Clin. Biochem. 2005, 38:328-334.
49. FDA Guidance for Industry Bioanalytical Method Validation 2001, Center for Drug Evaluation and Research of the U.S. Department of Health and Human Services Food and Drug Administration.
50. Bakhtiar R., Lohne J., Ramos L., Khemani L., Hayes M., Tse F. High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2002, 768:325-340.
51. Cortes J., Jabbour E., Kantarjian H., Yin C.C., Shan J., O'Brien S., Garcia-Manero G., Giles F., Breeden M., Reeves N., Wierda W.G., Jones D. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 2007, 110:4005-4011.
52. Shah N.P., Skaggs B.J., Branford S., Hughes T.P., Nicoll J.M., Paquette R.L., Sawyers C.L. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J. Clin. Invest. 2007, 117:2562-2569.
53. Baietto L., D'Avolio A., De Rosa F.G., Garazzino S., Michelazzo M., Ventimiglia G., Siccardi M., Simiele M., Sciandra M., Di Perri G. Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma. Anal. Bioanal. Chem. 2010, 396:791-798.
54. Baietto L., D'Avolio A., De Rosa F.G., Garazzino S., Patanella S., Siccardi M., Sciandra M., Di Perri G. Simultaneous quantification of linezolid, rifampicin, levofloxacin, and moxifloxacin in human plasma using high-performance liquid chromatography with UV. Ther. Drug. Monit. 2009, 31:104-109.
55. Baietto L., D'Avolio A., Ventimiglia G., De Rosa F.G., Siccardi M., Simiele M., Sciandra M., Di Perri G. Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma. Antimicrob. Agents Chemother. 2010, 54:3408-3413.
56. D'Avolio A., Baietto L., Siccardi M., Sciandra M., Simiele M., Oddone V., Bonora S., Di Perri G. An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients. Ther. Drug Monit. 2008, 30:662-669.
57. D'Avolio A., Sciandra M., Siccardi M., Baietto L., de Requena D.G., Bonora S., Di Perri G. A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2007, 848:374-378.
58. D'Avolio A., Siccardi M., Sciandra M., Baietto L., Bonora S., Trentini L., Di Perri G. HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2007, 859:234-240.
59. D'Avolio A., Simiele M., Baietto L., Siccardi M., Sciandra M., Patanella S., Bonora S., Di Perri G. A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients. Ther. Drug Monit. 2010, 32:86-92.
60. D'Avolio A., Simiele M., Siccardi M., Baietto L., Sciandra M., Bonora S., Di Perri G. HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions. J. Pharm. Biomed. Anal. 2010, 52:774-780.